EUVIMEDEUVIMED entdecken
Vergleichsstudie

Elexacaftor/tezacaftor/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls

Suzanne Kroes, Marlou C Bierlaagh, Juliet W Lefferts, Alessandra Boni, Danya Muilwijk, Carla Viscomi, Natascha D A Keijzer-Nieuwenhuijze, Luca Cristiani, Paul J Niemöller, Tibo F Verburg, Renato Cutrera, Alessandro G Fiocchi und 5 weitere

Journal of Cystic Fibrosis · 2025-01 · 24 (1) · 175-182

DOI: 10.1016/j.jcf.2024.09.019 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Cystic Fibrosis, 2025-01. Verfasst von Suzanne Kroes und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, 3584 EA Utrecht, the Net…. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis, Quinolones, Aminophenols. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis is a life-shortening genetic disease caused by pathological variants of the cystic fibrosis transmembrane conductance regulator gene. The CFTR modulator therapy elexacaftor, tezacaftor and ivacaftor (ETI) rescues CFTR protein function and has made a significant impact on the lives of many people with CF. In Europe, ETI is currently available for people with CF who have at least one F508del mutation whilst the effect of ETI on rare CFTR variants remains unknown, albeit that many of such variants may be restored through ETI. Italy has a high prevalence of rare CFTR variants compared to the rest of Europe, potentially leading to significant undertreatment of people with rare CFTR variants. In this study, we used patient-derived intestinal organoids to identify individuals harboring rare CFTR variants who might benefit from ETI modulator therapy. Two CFTR-dependent readouts (steady-state lumen area and forskolin-induced swelling) in intestinal organoids were characterized to assess CFTR function rescue upon ETI incubation. Functional restoration by CFTR modulators was compared to wild type CFTR function, ETI-treated organoids harboring genotypes currently eligible for ETI therapy (F508del/class I) and organoids harboring non-responsive genotypes. Our data showed in vitro response to ETI within or beyond the range of CFTR function associated with F508del-ETI in 19 out of 28 organoids. This suggest that a large percentage of people with rare CFTR variants without access to ETI may benefit from this treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic Fibrosis Transmembrane Conductance RegulatorCystic FibrosisQuinolonesAminophenolsOrganoidsBenzodioxolesPyridinesIndolesPyrrolidinesPyrazolesHumansDrug CombinationsChloride Channel AgonistsMutationQuinolines

Stichwörter der Autor:innen

CFTR modulator therapyCystic fibrosisElexacaftor/tezacaftor/ivacaftor (ETA)Intestinal organoidsTheratyping, theranostics

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorQuinolonesAminophenolsBenzodioxolesPyridinesIndolesivacaftorDrug CombinationselexacaftorPyrrolidines

Autor:innen und Institutionen

  • Department of Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, 3584 EA Utrecht, the Netherlands; Regenerative Medicine Utrecht, University Medical Center, Ut…
  • Department of Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, 3584 EA Utrecht, the Netherlands.
  • Pneumology and Cystic Fibrosis Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy.
  • Allergy Division, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy.
  • Cystic Fibrosis Center, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy.
  • Department of Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, 3584 EA Utrecht, the Netherlands. Electronic address: j.beekman@umcutrecht.nl.

Zitieren

APA

Kroes, S., Bierlaagh, M. C., Lefferts, J. W., Boni, A., Muilwijk, D., Viscomi, C., Keijzer-Nieuwenhuijze, N. D. A., Cristiani, L., Niemöller, P. J., Verburg, T. F., Cutrera, R., Fiocchi, A. G., Lucidi, V., van der Ent, C. K., Beekman, J. M., Alghisi, F., & Ciciriello, F. (2025). Elexacaftor/tezacaftor/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls. Journal of Cystic Fibrosis, 24(1), 175-182. https://doi.org/10.1016/j.jcf.2024.09.019

Vancouver

Kroes S, Bierlaagh MC, Lefferts JW, Boni A, Muilwijk D, Viscomi C, et al. Elexacaftor/tezacaftor/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls. Journal of Cystic Fibrosis. 2025;24(1):175-182. doi:10.1016/j.jcf.2024.09.019

BibTeX
@article{Kroes2025,
  author = {Kroes, Suzanne and Bierlaagh, Marlou C and Lefferts, Juliet W and Boni, Alessandra and Muilwijk, Danya and Viscomi, Carla and Keijzer-Nieuwenhuijze, Natascha D A and Cristiani, Luca and Niemöller, Paul J and Verburg, Tibo F and Cutrera, Renato and Fiocchi, Alessandro G and Lucidi, Vincenzina and van der Ent, Cornelis K and Beekman, Jeffrey M and Alghisi, Federico and Ciciriello, Fabiana},
  title = {Elexacaftor/tezacaftor/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  volume = {24},
  number = {1},
  pages = {175--182},
  doi = {10.1016/j.jcf.2024.09.019}
}
Kostenlos starten →